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Abstract 
Objective: We examined effects, costs, and patient/carer views of pharmacological 
management strategies for Lewy body dementia. Method: Studies were identified through 
bibliographic databases, trials registers, grey literature, reference lists and experts. We 
searched the terms ‘Lewy OR parkinson’ AND ‘dementia’ until May 2015 using the following 
inclusion criteria: participant diagnoses of Lewy body dementia, dementia with Lewy bodies 
or Parkinson’s disease dementia (or their carers); investigation of pharmacological 
management strategies; outcome measures and test scores reported. Data extraction and 
quality assessment were conducted by at least two authors. We undertook meta-analyses 
or provided summaries when studies could not be combined. Results: Forty-four studies 
were included in the review, examining 22 strategies. Meta-analysis indicated beneficial 
effects of donepezil and rivastigmine for cognitive and psychiatric symptoms. Rivastigmine, 
but not donepezil, was associated with greater risk of adverse events. Meta-analysis of 
memantine suggests it is well tolerated but with few benefits. Descriptive summaries 
provide some evidence for galantamine, modafinil, levodopa, rotigotine, clozapine, 
duloxetine, clonazepam, ramelteon, gabapentin, zonisamide, and yokukansan. Piracetam, 
amantadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do not appear 
to be effective. Conclusions: High level data regarding pharmacological strategies for 
managing Lewy body dementia is rare. Strategies for important areas of need in Lewy body 
dementia such as autonomic symptoms and carer burden have not been investigated, nor 
have the views of patients and carers about pharmacological strategies. 
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Introduction 
Lewy body dementia is a common cause of degenerative dementia in older people, 
accounting for 3.2 – 15.4% of cases (1, 2). It is characterised by impairments and fluctuations 
in cognition, recurrent visual hallucinations, and motor features of parkinsonism. Other 
significant features include sleep disorders, depression, delusions, and autonomic 
dysfunction (3, 4). The term Lewy body dementia is used here to include two related 
disorders: dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). 
Comparisons suggest broad overlap clinically, though executive impairment, delusions, and 
hallucinations might be more common in DLB (5, 6). For diagnosis, PDD is applied when 
motor symptoms occur at least one year before dementia, and DLB when dementia 
precedes or is closely followed by motor symptoms (4). 
 
While a range of pharmacological strategies are used in an attempt to ameliorate the 
symptoms of Lewy body dementia, and clinical guidelines have recommended 
cholinesterase inhibitors for cognitive and psychiatric symptoms, the current evidence for 
management options for the range of symptoms is limited and there remains no unified 
evidence-based management care pathway (7 – 10). 
 
To develop effective approaches to care it is necessary to establish which strategies are 
effective and to determine whether DLB and PDD are amenable to the same treatments. In 
this paper we review pharmacological management strategies examining three questions: 
(1) what are their benefits, harms and costs in the disorders, (2) what views do patients and 
carers have of these strategies, (3) how, when and where should they be implemented? 
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Methods 
The review protocol is registered at PROSPERO (registration number CRD42014007180, 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014007180). 
 
Search strategy 
Studies were identified through bibliographic databases, trials registers and, grey literature 
(see published protocol for full details). Reference lists of relevant studies and previously 
systematic reviews were also examined and input sought from Lewy body dementia experts. 
We used the keywords “Lewy or parkinson” and “dementia”, conducting searches until May 
2015, without restrictions on time or language.  
 
Study selection 
Titles and abstracts were screened independently by LL, EMa, EMi and CS, with non-English 
language papers screened by native speakers. Discrepancies were resolved through 
discussion between screeners. Potentially relevant studies were obtained in full and 
examined in detail by CS against the following criteria: (1) participants had a diagnosis of 
DLB, PDD, or Lewy body dementia (or were their carers), (2) studies examined 
pharmacological strategies, and (3) outcome measures and scores were specified. No 
restrictions were placed on study designs but opinion papers were excluded (see online 
supplementary figure S1 for study flowchart).  
 
Data extraction 
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Data were extracted by EMi and CS and recorded in an Excel database. We collected 
information relating to participant demographics, selection criteria, study design, 
management strategies, outcome measures, adverse events, and withdrawals.  
 
Data synthesis 
Studies were grouped and analysed according to pharmacological strategy. For each strategy, 
studies of the highest level of evidence were included in the review. Classification of level of 
evidence was determined using guidelines from the Oxford Centre for Evidence-Based 
Medicine (11). 
 
Methodological quality 
Methodological quality was assessed by VC, EMi and CS using the Quality Assessment Tool 
for Quantitative Studies (QATQS, www.ephpp.ca/tools.html) (12). This tool examines 
selection bias, study design, confounders, blinding, data collection methods, withdrawals 
and dropouts. Domains are rated as weak, moderate or strong quality, which feed into an 
overall rating of study quality. Reliability and validity of the QATQS have been demonstrated 
(13). The tool was developed to assess quality across study designs, aiding consistency and 
clarity of reporting.  
 
Statistical analysis 
Meta-analysis was conducted using Revman 5.3 (Cochrane Collaboration, 
www.tech.cochrane.org/revman/download), employing the inverse variance method. 
Heterogeneity was assessed using chi-squared and I-squared (I2) statistics and considered 
significant with chi-squared p value < .10 and I2 > 40%. We employed random-effects 
 
 
7 
 
models when there was significant study heterogeneity and fixed-effect models when 
heterogeneity was not significant. Missing data were sought from study authors and 
estimated using methods outlined in the Cochrane Handbook for Systematic Reviews of 
Interventions if not obtainable (14).  We estimated risk ratio with 95% confidence intervals 
(CI) for dichotomous outcomes and weighted mean difference or standardised mean 
difference with 95% CI for continuous outcomes. Descriptive summaries were provided 
when studies could not be combined. 
 
Results 
The titles and abstracts of 28,568 records were screened; 26,966 did not meet inclusion 
criteria. Assessment of 633 full articles was conducted; 197 met our inclusion criteria and 44 
were included as the highest level of evidence for 22 pharmacological strategies (see online 
supplementary table S1 for characteristics of included studies).  
 
MANAGEMENT STRATEGIES 
Donepezil and Rivastigmine 
Data from studies of donepezil and rivastigmine were combined and examined using meta-
analysis to obtain an estimate of their combined and separate effects (no randomised 
controlled trials were identified for galantamine; discussed later). The highest level of 
evidence for donepezil was randomised controlled trials, two for DLB and four for PDD (15-
20); for rivastigmine there was one randomised controlled trial each for DLB and PDD (21-
22). The highest level of evidence of donepezil for visual hallucinations (a key symptom of 
Lewy body dementia) was an uncontrolled trial (23). The highest level of evidence for 
withdrawal of donepezil was an open label study (24). We identified three ongoing studies 
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examining donepezil for cognition, psychiatric symptoms, and functional ability 
(clinicaltrials.gov, trial numbers: NCT00776347, NCT01014858 umin.ac.jp, trial number: 
UMIN000010752, and one study to develop a predictive test to identify which cholinergic 
medication should be prescribed first (clinicaltrials.gov, trial number: NCT01944436). 
 
Five studies examined clinician impression of change of global outcomes; four trials 
examined improvement figure 1a) (15 – 17, 22), three examined absence of deterioration 
(figure 1b) (15, 17, 22), and four trials examined impression of change as a continuous 
outcome measure (16, 17, 19, 22) (see online supplementary figure S2a). Scores were 
estimated for one trial (15). Analysis of improvement data indicated that participants treated 
with cholinesterase inhibitors were more frequently rated as improved than those receiving 
placebos (45% vs 34%; risk ratio 1.37, 95% CI 1.15, 1.62). Subgroup analyses indicated that 
compared to placebo improvement was more likely for donepezil in DLB (64% vs. 33%, risk 
ratio 1.93, 95% CI 1.08, 3.43) and PDD (49% vs. 38%, risk ratio 1.29, 95% CI 1.02, 1.63), and 
rivastigmine in PDD (40% vs. 29%, risk ratio 1.37, 95% CI 1.05, 1.79). Analysis of absence of 
deterioration data indicated that participants treated with cholinesterase inhibitors were 
more frequently rated as not deteriorating than those receiving placebos (71% vs 62%; risk 
ratio 1.26, 95% CI 1.01, 1.57), but with considerable heterogeneity (I2 = 76%). Subgroup 
analyses indicated that absence of deterioration was more common in participants with DLB 
treated with donepezil (96% vs. 50%, risk ratio 1.93, 95% CI 1.34, 2.78), but with no between 
group difference in PDD for donepezil (p = 0.18) or rivastigmine (p = 0.07). Analysis of 
continuous data indicated that mean change scores were 0.55 points lower (suggesting 
improvements) in participants treated with cholinesterase inhibitors (95% CI -0.82, -0.28), 
but with significant heterogeneity (I2 = 52%). Subgroup analysis indicated benefits of 
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donepezil in DLB (weighted mean difference -1.13, 95% CI -1.66, -0.60) and PDD (weighted 
mean difference -0.37, 95% CI -0.60, -0.14), and rivastigmine in PDD (weighted mean 
difference -0.50, 95% CI -0.77, -0.23). 
 
Eight studies assessed cognition using the MMSE (15 – 22) (figure 1c). Standard deviations 
(SD) were estimated in three trials (17, 18, 21). Mean change scores were 1.26 points higher 
(suggesting improvements) in participants receiving cholinesterase inhibitors (95% CI 0.66, 
1.86). In subgroup analysis benefits were seen for donepezil in DLB (weighted mean 
difference 1.93, 95% CI 1.01, 2.85) and rivastigmine in PDD (weighted mean difference 1.00, 
95% CI 0.33, 1.67), but not for rivastigmine in DLB (p = 0.11) or donepezil in PDD p = 0.52). 
 
Six studies used the Neuropsychiatric Inventory (NPI-10) to assess psychiatric symptoms (15, 
17, 18, 20 - 22) (figure 1d). SD were estimated in two trials (17, 18). There were no 
significant between group differences (p = 0.46), but significant heterogeneity (i2 = 79%). 
Subgroup analyses indicated benefits on total psychiatric symptoms in PDD of donepezil 
(weighted mean difference -1.17, 95% CI –2.26, -0.08) and rivastigmine (weighted mean 
difference -2.00, 95% CI -3.91, -0.09), but not for donepezil (p = 0.52) or rivastigmine (p = 
0.17) in DLB. Two studies assessed psychiatric symptoms in DLB using the NPI-4 (the sum of 
scores of apathy, delusions, depression, and hallucinations) (15, 21). A significant effect, 
favouring cholinesterase inhibitors, was observed (weighted mean difference -3.36, 95% CI -
8.63, -0.97). Subgroup analysis indicated a benefit for participants receiving donepezil 
(weighted mean difference -4.80, 95% CI -8.63, -0.97) but not rivastigmine (p = 0.17) (see 
online supplementary figure S2b). Generally, subscales scores for the NPI have not been 
reported. McKeith and colleagues and Mori and colleagues presented these graphically. 
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From 95% CI, rivastigmine does not appear to have beneficial effects on subscale items in 
DLB, but donepezil may be beneficial for delusions, hallucinations, and cognitive 
fluctuations. In PDD, donepezil was not beneficial in the treatment of hallucinations, 
hostility, suspiciousness, or unusual thought content (19). In an uncontrolled trial examining 
donepezil for hallucinations in DLB (n = 13), scores were 4.6 points lower on the BEHAVE-AD 
following treatment, suggesting improvements (23). 
 
Three studies investigated activities of daily living in PDD using the Alzheimer’s Disease Co-
operative Study - Activities of Daily Living Inventory, Disability Assessment for Dementia, 
and Unified Parkinson’s Disease Rating Scale – Activities of Daily Living (17, 18, 22) (see 
online supplementary figure S2c). SD were estimated in two trials (17, 18). A significant 
effect of cholinesterase inhibitors was observed (standardised mean difference 0.2, 95% CI 
0.07, 0.34), with subgroup analysis indicating a benefit of rivastigmine (standardised mean 
difference 0.20, 95% CI 0.02, 0.40), but not donepezil (p = 0.06). 
 
Eight studies reported adverse events and withdrawals (15 – 22; see online supplementary 
material S2d + e). Adverse events were more common in participants treated with 
cholinesterase inhibitors (80% vs 70%, risk ratio 1.13, 95% CI 1.06, 1.21). Subgroup analysis 
indicated a greater risk ratio in DLB (91% vs. 75%, risk ratio 1.21, 95% CI 1.03, 1.43) and PDD 
(83% vs. 70%, risk ratio 1.18, 95% CI 1.06, 1.31) for rivastigmine, but not for donepezil in DLB 
(p = 0.25) or PDD (p = 0.31). Adverse events reported more frequently in treatment than 
placebo groups were nausea (rivastigmine: DLB and PDD; donepezil: PDD), vomiting 
(rivastigmine: DLB and PDD), anorexia (rivastigmine: DLB), tremor (rivastigmine: PDD), 
somnolence (rivastigmine: DLB), dizziness (rivastigmine: PDD), and insomnia (donepezil: 
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PDD). Further, 25% of participants treated with cholinesterase inhibitors withdrew from 
studies compared to 17% of those receiving placebos (risk ratio 1.47, 95% CI 1.16, 1.85). 
Subgroup analysis indicated that the risk was significantly greater for participants with PDD 
treated with donepezil (23% vs. 15%, risk ratio 1.51, 95% CI 1.03, 2.23) and rivastigmine 
(27% vs. 17%, risk ratio 1.55, 95% CI 1.22, 1.97) but not for participants with DLB treated 
with donepezil (p = 0.68) or rivastigmine (p = 0.08). There were no between group 
differences in motor function (weighted mean difference -1.67, 95% CI -4.02, 0.69), as 
assessed by four studies using the Unified Parkinson’s Disease Rating Scale -III (15, 16, 18, 
19) (see online supplementary figure S2f), with SD estimated in one trial (18).  
 
++ Figure 1 ++ 
 
Results of an uncontrolled trial suggest that sudden withdrawal of cholinesterase inhibitors 
might be associated with deteriorations in cognition in DLB and PDD (MMSE: -4.4 and -3.5 
points, respectively), and increased psychiatric symptoms (NPI change = 22) for PDD (24). 
 
Galantamine 
The highest level of evidence for galantamine was an uncontrolled trial in DLB and a 
controlled trial in PDD (25, 26). In DLB (n = 50), improvements were reported for cognitive 
fluctuations (1-day fluctuations scale change = -1.8), sleep disturbances (Pittsburgh Sleep 
Quality Index change = -3.2), and psychiatric symptoms (NPI change = -8.2) (25). Inconsistent 
results were reported for cognition. In PDD (galantamine n = 21, treatment as usual n = 20) 
improvements were reported for cognition (MMSE change difference = 4.9), total psychiatric 
symptoms (NPI change difference = 8.9), hallucinations (NPI hallucinations change difference 
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= 4.1), anxiety (NPI anxiety change difference = 0.7), apathy (NPI apathy change difference = 
3.9), and sleep (NPI sleep change difference = 1.4), that favoured treatment with 
galantamine (26). 
 
Memantine 
The highest level of evidence for memantine was one randomised controlled trial for PDD 
and two for mixed DLB and PDD samples (26-28). Three studies examined clinician 
impression of change; three examined improvement (figure 2a) (27 - 29), two absence of 
deterioration (27, 29) (see online supplementary figure S3a), and two continuous data see 
online supplementary figure S3b (27, 29). There were no between group differences for 
improvement (p = 0.09) or absence of deterioration (p = 0.07). Analysis of continuous data 
indicated mean change scores were significantly lower (0.40 points) in participants treated 
with memantine (95% CI -0.71, -0.10), suggesting improvements. Subgroup analysis 
indicated that this difference was significant for DLB (weighted mean difference -0.60, 95% 
CI -1.16, -0.04) but not PDD (p = 0.34). 
 
Two studies assessed cognition using the MMSE (28, 29) (see online supplementary figure 
S3c, indicating no between group differences (p = 0.52). Three studies used the NPI to assess 
psychiatric symptoms (27 - 29) (see online supplementary figure S3d), with SD estimated in 
two trials (27, 28). There were no between group differences (p = 20). The effect of 
memantine on activities of daily living was investigated in two studies, one using the 
Alzheimer’s Disease Co-operative Study - Activities of Daily Living Inventory and one the 
Disability Assessment for Dementia (see online supplementary figure S3e) (27, 28). There 
were no between group differences (p = 0.30). Three trials reported adverse events (see 
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online supplementary figure S3f) and withdrawals (see online supplementary figure S3g) (27 
- 29). There were no between group differences for adverse events (p = 0.94) or withdrawals 
(p = 0.68). Further, there was no difference between the groups on the Unified Parkinson’s 
Disease Rating Scale -III (p = 0.34) (see online supplementary S3h). 
++ Figure 2 ++ 
 
 Armodafinil/modafinil 
The highest level of evidence for armodafinil was an uncontrolled trial (sleep) and a case 
series (global impression) in DLB, a case series (global impression) in PDD, and an 
uncontrolled trial (attention) in Lewy body dementia (30, 31). Results for DLB (n = 17) 
suggest that treatment with armodafinil is associated with increased wakefulness (30). Data 
from self-reports and computer-based reaction tasks in Lewy body dementia (n = 7) suggest 
improvements in subjective alertness and reflexive attention (31). In a retrospective review 
of treatment with modafinil or armodafinil (DLB n = 2, PDD n = 4) 50% of individuals were 
rated by clinicians as minimally improved, 33% as much improved and 17% as not improved 
(31). 
 
Piracetam 
The highest level of evidence for piracetam in PDD was a randomised controlled trial (n = 20) 
(32). No between group differences were observed in terms of cognition, motor function, or 
functional ability, except on a single subscale (engagement in recreational activities) which 
favoured the piracetam group. No studies of piracetam for DLB were identified. 
 
Discontinued drugs 
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A small number of studies of metrifonate and tacrine were identified in our search. These 
drugs have been discontinued and are not discussed here. 
 
Antiparkinsonian medications 
Levodopa 
The highest level of evidence for levodopa in DLB and PDD was four uncontrolled trials (33 - 
36). The highest level of evidence for levodopa withdrawal in PDD was a randomised 
controlled trial (37). Examinations of acute and chronic effects of levodopa suggest 
improvements in motor functioning and reductions in tremor for individuals with DLB and 
PDD (33 - 35). Beneficial effects of levodopa (i.e. 10% or more improvement in Unified 
Parkinson’s Disease Rating Scale -III score) were more common in PDD (65 – 70%) than DLB 
(32 – 50%) (33, 34, 36), though approximately one third of those who derive motor benefits 
experienced increases in psychotic symptoms (34).  
 
A randomised controlled trial examined withdrawal of levodopa in PDD (n = 11) showing that 
removing levodopa did not result in worsening cognition, motor functioning or psychiatric 
symptoms (37).  
 
Amantadine 
The highest level of evidence for amantadine in PDD was an uncontrolled trial (PDD n = 10, 
Parkinson’s disease and cognitive impairment n = 15) (38). For participants with dementia, 
no significant effects of amantadine were observed on 13 out of 15 cognitive tests. 
Statistically significant improvements were observed on total Frontal Assessment Battery 
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score (3 points) and the Inhibitory Control subscale (0.3 points). No studies of amantadine 
for DLB were identified.  
 
Rotigotine 
The highest levels of evidence for rotigotine in PDD were one uncontrolled trial (Parkinson’s 
disease severity) and one case series (anxiety) (39, 40). Degree of disability due to 
Parkinson’s disease (n = 9) and anxiety (n = 2) were rated as less severe after treatment 
(Unified Parkinson’s Disease Rating Scale change = -12; Hamilton Anxiety Rating Scale 
change = -23). No studies of rotigotine for DLB were identified. 
  
Selegiline 
The highest level of evidence for selegiline in Parkinson’s disease dementia was a cohort 
study (PDD n = 4, Parkinson’s disease without dementia = 3) (41). No beneficial effects were 
observed for participants with dementia on measures of behaviour, cognition and motor 
function. No studies of selegiline for DLB were identified.  
  
Antipsychotics 
Clozapine 
The highest level of evidence for clozapine in PDD was a chart review (PDD n = 8, ‘other 
dementia’ n = 8) (42). Scores on the Brief Agitation Rating Scale (-2.4) and Cohen-Mansfield 
Agitation Inventory (- 4.2) were significantly lower in the PDD group after treatment, with 
62.5% of patients rated as much improved. Side effects included drooling, sedation, 
tremors, constipation and delirium. No studies of clozapine for DLB were identified.  
 
 
 
16 
 
Olanzapine 
The highest level of evidence for olanzapine was a secondary analysis of a randomised 
controlled trial of Alzheimer’s disease, with participants retrospectively identified as 
meeting DLB criteria, and an uncontrolled trial in PDD (43, 44). In participants with possible 
DLB (n = 29), those treated with 5mg (n = 10) of olanzapine showed greater reductions in 
scores on the NPI subscales of delusions (-3.8 points) and hallucinations (-5.9 points) than 
those receiving placebo (n = 10). No significant differences were observed between placebo, 
10mg and 15mg groups (43). While no side effects were reported in this study, other authors 
have suggested that around 38% of people with DLB do not tolerate olanzapine even at low 
doses (2.5mg) (45). In a sample of participants with PDD (n = 3), reductions in NPI delusion (-
3.2 points), NPI hallucination (-0.97) and total psychiatric symptoms (NPI: - 15.1 points, 
Behavioural Pathology in Alzheimer’s Disease: -15 points) have been reported (44). 
Worsening of motor functioning and psychiatric symptoms are reported in 33 – 80% of 
individuals with PDD following olanzapine treatment (44, 46). 
 
Quetiapine 
The highest level of evidence for quetiapine was a case series in DLB, a retrospective chart 
review in PDD, and a randomised controlled trial in Lewy body dementia (47 - 49). 
Reductions in psychiatric symptoms were reported for 6 out of 9 individuals with DLB 
following treatment with quetiapine (change in sum of NPI delusions + hallucinations + 
agitation/aggression = 7.7) (47). However, 33% of participants withdrew due to adverse 
events. For individuals with PDD and drug-induced psychosis, quetiapine was associated 
with worsening cognition and motor functioning without improvements to psychiatric status 
(48).  A randomised controlled trial of Lewy body dementia (DLB n = 23, PDD n = 9, 
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Alzheimer’s disease with parkinsonian features n = 8) revealed no between group 
differences on measures of psychiatric symptoms, cognition, activities of daily living, motor 
function or clinician’s impression of change (49). 
 
Risperidone 
The highest level of evidence for risperidone was a randomised trial in DLB and an 
uncontrolled trial in Parkinson’s disease dementia (50, 51). In participants with PDD and 
psychosis (n = 9) significant reductions were observed on the total score of the Brief 
Psychiatric Rating Scale (-9.5 points) and Cohen-Mansfield Agitation Inventory (-9.6 points), 
and improvements in social, occupational and psychological functioning (Global Assessment 
of Functioning change = 17 points) (50). No side effects were reported. In DLB, risperidone 
does not appear to be well tolerated; results of a randomised controlled trial (n = 31) 
suggest deterioration in cognition (MMSE change = -2.3 points), worsening psychiatric 
symptoms (NPI change = 17.3 points) and study withdrawal (65%) (51). 
 
Antidepressants 
Citalopram/escitalopram, duloxetine and trazodone 
The highest level of evidence for antidepressants was a randomised trial of citalopram in 
DLB (51) and an unpublished trial of duloxetine, escitalopram, and trazodone in PDD 
(52).Citalopram does not appear to be efficacious or well tolerated in DLB, with 10 out of 14 
participants (71.4%) withdrawing due to adverse effects (51). In a trial of antidepressants for 
depression in PDD, participants treated with duloxetine (n = 8) experienced reductions in 
total Montgomery Asberg Depression Rating Scale score (-18.6 points) (52). Individuals 
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receiving escitalopram, (n = 7) and trazodone (n = 8) were reported to have reductions in 
depressive symptoms, but scores were not provided. 
 
Sedatives 
Clonazepam 
The highest level of evidence for clonazepam in DLB was a case series in which two out of 
three participants experienced reductions in the number of nights on which episodes of 
sleep disturbance occurred (53). No studies of clonazepam for PDD were identified.  
 
Ramelteon 
The highest level of evidence for ramelteon in DLB was a case series (54). Descriptive 
statistics indicated reductions in neuropsychiatric symptoms, sleep disturbances and self-
reported carer burden, with no adverse effects. No studies of ramelteon for PDD were 
identified.  
 
Anticonvulsants 
Gabapentin 
The highest level of evidence for gabapentin was case reports, one for DLB (55) and one for 
PDD (56). Following treatment, reductions were reported in symptoms of restless leg 
syndrome (DLB) and agitation (PDD). 
 
Zonisamide 
The highest levels of evidence for zonisamide were case series for DLB (57) and PDD (58). 
Descriptive reports of DLB (n = 3) suggest improvements in daily living skills, motor, and 
 
 
19 
 
carer burden in mild dementia and a reduction in psychiatric symptoms in severe dementia 
(57). Similar results were reported in a single case of PDD (58). Randomised controlled trials 
of zonisamide for motor function (clinicaltrials.jp, trial number: JapicCTI-122040) and 
psychiatric symptoms (umin.ac.jp, trial number: UMIN000010631) are currently underway. 
 
Herbal medicines 
Yokukansan 
The highest level of evidence for yokukansan was a randomised crossover trial in DLB and an 
uncontrolled trial in PDD (59, 60). In participants with DLB randomised to receive 
yokukansan followed by no treatment (group A, n = 9) or no treatment followed by 
yokukansan (group B, n = 6) reductions were reported in psychiatric symptoms in both 
groups (NPI change Group A = -10.1 points; Group B = -12.4 points); this was statistically 
significance in group A only (59). In a trial of participants with PDD (n = 7) there were 
significant difference in pre- and post-treatment scores for total psychiatric symptoms (-6 
points) and visual hallucinations (-2.6 points), but no differences on any other NPI subscales 
(60). 
 
PATIENT AND CARER VIEWS OF MANAGEMENT STRATEGIES 
No studies were identified that examined the views of patients/carers about 
pharmacological strategies for Lewy body dementia. 
 
COST-EFFECTIVENESS ANALYSIS 
Two studies reported economic data (61, 62). Estimates of cost per quality of life year gained 
from treatment with cholinesterase inhibitors in Alzheimer’s disease and DLB suggested 
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lower costs in the DLB group (61). However, in the DLB group there was considerable 
variability in the estimates of three models (micro-simulation = £2,706, Markov = £35,922, 
Southampton Health Technology Assessment Centre = £46,794). In a study of rivastigmine 
for PDD, no significant between group differences were reported for quality-adjusted life 
days or total costs (62). 
 
Discussion 
We conducted a systematic review of pharmacological strategies for Lewy body dementia, 
identifying 28,568 potentially relevant papers. Forty-four papers were included, examining 
22 pharmacological strategies. High level evidence was rare, with only 17 randomised 
controlled trials.  Methodological quality was rated as weak for 41% of included studies, 
moderate for 39%, and strong for 20%. 
 
Data from controlled trials were available for donepezil, rivastigmine, galantamine, 
memantine, olanzapine, risperidone, piracetam, quetiapine, citalopram, and yokukansan. 
Meta-analyses indicated improvements with donepezil and rivastigmine for cognition, global 
psychiatric symptoms (PDD only), hallucinations, delusions, and activities of daily living 
(without worsening motor symptoms of parkinsonism) but with adverse events. This is 
consistent with prior reviews of cholinesterase inhibitors for Lewy body dementia (7, 9). 
Evidence for galantamine suggests potential benefits for psychiatric symptoms and possibly 
cognition, but data are limited. Memantine appears to be well tolerated, but with few 
benefits to participants. Consistent with previous meta-analyses, memantine was only 
superior to placebo in terms of impression of change when analysed as a continuous 
outcome measure; this advantage was not observed when analysed as categorical data in 
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terms of improvement or absence of deterioration. Recently published secondary analyses 
of memantine suggest some statistical advantages of memantine over placebo in relation to 
aspects of attention, sleep, carer burden, aspects of quality of life, and goal attainment (63 - 
66). For olanzapine and quetiapine, reductions in psychiatric symptoms appear limited by 
high levels of adverse events. Citalopram, piracetam, and risperidone do not appear to be 
beneficial. Data regarding yokukansan for psychiatric symptoms is mixed.  
 
There was weak evidence for potential efficacy of armodafinil/modafinil, levodopa, 
zonisamide, ramelteon, clonazepam, gabapentin, rotigotine, duloxetine, escitalopram, 
trazodone, and clozapine. These studies did not include controls so we can only conclude 
that there could be an association between interventions and benefits to participants. 
Amantadine and selegiline do not appear to be effective for managing symptoms of Lewy 
body dementia, but data are available from only single trials and/or small samples. Overall, 
we must be cautious not to overstate the apparent effects/lack of effects given how few high 
levels studies are available for each strategy. 
 
Limited data are available about costs of pharmacological strategies. We identified two 
studies indicating that donepezil and rivastigmine might not be cost effective as treatment 
costs are not significantly different compared to placebo groups, and estimates are typically 
above the threshold of £30,000 per QALY for treatment, a cut-off often considered cost-
effective. However, patents on these drugs have since expired and cheaper generic versions 
are now available.  
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Associations between strategy efficacy and participant characteristics have rarely been 
investigated. To date, only a small number of studies has investigated associations between 
treatment efficacy and participant characteristics. Results, which must be treated with 
caution, suggest a better response to levodopa for younger participants with DLB (36), a 
greater benefit from rivastigmine for cognition (global cognition, attention) in those who 
hallucinate (67, 68), and that participants with elevated plasma homocysteine experience a 
greater benefit of rivastigmine on aspects of cognition and global neuropsychiatric 
symptoms (69). In general, there is insufficient evidence about how, when and where 
management strategies should be implemented. 
 
Differing treatment effects between DLB and PDD have received little attention, but some 
differences are apparent. For example, benefits of quetiapine on psychiatric symptoms for 
some people with DLB compared to a general lack of efficacy and adverse effects in PDD (47, 
48), while levodopa appears to be more beneficial for PDD than DLB (36). Our meta-analyses 
suggest that the effects of donepezil and rivastigmine are comparable for DLB and PDD. 
Other studies suggest similar effects of donepezil in both groups (70). Overall, a lack of direct 
comparison hampers our ability to clarify differences in treatment effects. An additional 
caveat is the uncertainty about whether DLB and PDD are separate diseases; the one-year 
rule for distinguishing the diagnoses is provided only as a guide for clinical practice (4). 
 
A notable outcome from our review is a potential disconnect between research trials and 
the reality of clinical practice and patients/carers preferences. For example, patient-related 
outcome and symptom-specific measures were rarely used, and apparent benefits of 
strategies were typically determined on the basis of statistical rather than clinical 
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significance. Further, no studies were identified concerning the views that people with Lewy 
body dementia /their carers have of management strategies. Future research that focuses 
on areas of need reported by people with Lewy body dementia and their families may 
provide useful information about which strategies to employ.  
 
This review has a number of limitations. First, the evidence-base is small. Even for the most 
well researched management strategies there were few randomised controlled trials. 
Second, there was a range of issues relating to risks of bias and study quality including open 
label study designs, no control groups, small samples (which might affect the power of 
studies to detect differences), and concurrent use of medications that might obscured the 
effects of study drugs. Furthermore, the accuracy of diagnostic criteria for DLB and PDD is 
not clear, with diagnoses in some cases applied retrospectively (43). Third, research into the 
management strategies for Lewy body dementia has usually taken the form of efficacy 
studies. While these are important in establishing therapeutic effects under highly controlled 
circumstances, the results are not necessarily generalisable to clinical practice. For example, 
in research trials samples are often homogeneous, interventions are standardised without 
scope for flexibility, concurrent treatments or co-morbid conditions are not allowed, and 
those with more severe difficulties might be less likely to participate/be recruited. 
Effectiveness studies provide a way to address some of these concerns. Fifth, it was 
necessary to estimate missing information for our meta-analyses as we were not able to 
obtain original data from study authors. Sixth, studies of management strategies that are 
used in clinical practice, and have been recommended in expert opinion reviews, were not 
included as data for DLB/PDD groups were not available. For example, in Parkinson’s disease 
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there is evidence from randomised controlled trials that pimavanserin and clozapine might 
be useful in treating psychotic symptoms in people with lower cognition (71). 
 
Concluding remarks 
In this comprehensive review of pharmacological strategies for DLB and PDD we have 
identified the current best evidence for many key areas of need. There remain substantial 
gaps in our knowledge of patient and carer experiences, cost effectiveness, how, when and 
with whom strategies should be implemented, and about how meaningfully the results of 
studies translate to clinical practice. 
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Figure 1. Forest plots for cholinesterase inhibitor trials 
1a. Forest plot of global outcomes on the Alzheimer's Disease Cooperative Study - Clinical 
Global Impression of Change (improvement): donepezil + rivastigmine vs. placebo. Four 
studies, n = 916 
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1b. Forest plot of global outcomes on the Alzheimer's Disease Cooperative Study - Clinical 
Global Impression of Change (absence of deterioration): donepezil + rivastigmine vs. 
placebo. Three studies, n = 892 
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1c. Forest plot of cognitive functioning on the MMSE: donepezil + rivastgimine vs. placebo. 
Eight studies, n = 1202 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
37 
 
1d. Forest plot of neuropsychiatric symptoms on the NPI-10: donepezil + rivastigmine vs. 
placebo. Six studies, n = 1118 
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Figure 2. Forest plot of global outcomes on the Alzheimer's Disease Cooperative Study - 
Clinical Global Impression of Change (improvement): memantine vs. placebo. Three studies, 
n =277 
 
